vitiligo. Vitiligo
Conditions
Interventions
Intervention 1: Intervention group: Co2 fractional laser (
Energy, 100mj
density, 100 / cm2
2 passes DEKA) with, dwell time: 400, power: 6 w, dot mode spacing: 550. 3 sessions with one month intervals and lamp excimer (Medflash II, Italy
308nm) twice a week for a maximum of 12 weeks starting at 0.5 J / cm2. In this group, in addition after the PRP preparation, we inject 0.1 cc of the solution into the patient's blood at a distance of
2 passes DEKA) with, dwell time: 400, power: 6 w, dot mode spacing: 550 Three sessions with one month intervals and lamp excimer (Medflash II, Italy
308nm) twice a week for a maximum of 12 weeks starting at 0.5 J / cm2. In this group, in addition to this topical cream Tacrolimus 0.1% of Tehran Shimi Pharmaceutical Company is used twice a day for 3
Sponsors
Kerman University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Suffering from vitiligo Age over 18 years They have not received any treatment for vitiligo for 3 months before enrollment Among the patients referred to Afzalipour Hospital, Besat Clinic and Dermatology Center The diagnosis is made clinically by a dermatologist Confirmation of the disease by means of examination with a Wood lamp
Exclusion criteria
Exclusion criteria: Uncontrolled systemic diseases renal failure history of allergy to calcineurin inhibitors and macrolides age under 18 segmental vitiligo involvement of more than 20% of the skin surface history of autoimmune disease and use of other treatments patient With a positive Coubern history history of colloid and pregnancy and lactation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lesion area. Timepoint: at base line and 1, 2, 3, 4, 5 and 6 months later. Method of measurement: Measure the diameters of the depigmented lesion using a ruler.;Disease activity. Timepoint: at base line and 1, 2, 3, 4, 5 and 6 months later. Method of measurement: Measurement of disease activity based on VIDA SCORE.;Percentage of improvement. Timepoint: at base line and 1, 2, 3, 4, 5 and 6 months later. Method of measurement: By clinical examination of the lesion and measuring the percentage of lesion healing compared to the primary lesion. | — |
Secondary
| Measure | Time frame |
|---|---|
| Erythema. Timepoint: at base line and 1, 2, 3, 4, 5 and 6 months later. Method of measurement: by physical examination and classification of the severity of adverse effects to mild , moderate and severe.;Scaling. Timepoint: at base line and 1, 2, 3, 4, 5 and 6 months later. Method of measurement: by physical examination and classification of the severity of adverse effects to mild , moderate and severe.;Pruritis. Timepoint: at base line and 1, 2, 3, 4, 5 and 6 months later. Method of measurement: by physical examination and classification of the severity of adverse effects to mild , moderate and severe.;Secondary. Timepoint: at base line and 1, 2, 3, 4, 5 and 6 months later. Method of measurement: With clinical examination of the lesions and the presence of signs of infection such as purulent discharge and hotness. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMaryam Khalili
Kerman University of Medical Sciences
Outcome results
None listed